Advertisement

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Welcome and Introduction to Vi3C

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Apr
16
Today In Oncology
Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC
Romiplostim for Chemotherapy-Induced Thrombocytopenia
AYA Cancer Survivors and Risk for Earlier Subsequent Primary Neoplasms
Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma
Is Standard of Care Optimal for the Individual Patient?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo